Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.

Inclusion Criteria: 1. Having clinical diagnosis of primary membranous nephropathy, as verified by biopsy. 2. Have positive anti-PLA2R autoantibody test results \> 20 relative units (RU)/ml. 3. During screening at least one testing of proteinuria must be \>3.5 g/24h. 4. Have nephrotic range proteinuria for at least 8 weeks prior to Day 1 and no improvement (\90% of Lower Limits of Normal Range.); Cyclophosphamide or Chlorambucil within 180 days;other immunosuppressive/immunomodulatory agents within 90 days;greater than 30mg/day prednisone or equivalence within 30 days. 6. Acute or chronic infection,including positivity of tuberculosis infection test. 7. Positive serology for TP,HIV, HBV, or HCV. 8. Lab testing abnormality as: WBC\< 3000/mm³, Lymphocyte \< 1000/ mm³, neutrophil \1.5×ULN. 9. Judged by the investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements.